Trial Profile
Evaluation of anthithrombin III therapeutic effect by frequency of administration in sepsis-associated disseminated intravascular coagulation
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 18 Oct 2019
Price :
$35
*
At a glance
- Drugs Antithrombin III (Primary)
- Indications Thrombosis
- Focus Therapeutic Use
- 16 Oct 2019 Status changed from not yet recruiting to discontinued.
- 17 May 2016 New trial record